EcoDrugPlus

Adrenoceptor Alpha 2b

Ensembl ID : ENSJJAG00000009163
Gene Symbol: ADRA2B
3 Cross references
219 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSJJAG00000017482
Gene Symbol: ADRB1
3 Cross references
161 Possible Orthologues:

Adrenoceptor Beta 3

Ensembl ID : ENSJJAG00000012860
Gene Symbol: ADRB3
3 Cross references
215 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSJJAG00000019529
Gene Symbol: AGER
3 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSJJAG00000010699
Gene Symbol: ADH5
3 Cross references
400 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSJJAG00000023402
Gene Symbol: AKR1B1
3 Cross references
429 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]

Ensembl ID : ENSJJAG00000011103
Gene Symbol: LOC101597358
2 Cross references
229 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSJJAG00000010815
Gene Symbol: LOC101597074
2 Cross references
229 Possible Orthologues:

Amine Oxidase Copper Containing 3

Ensembl ID : ENSJJAG00000018905
Gene Symbol: AOC3
3 Cross references
321 Possible Orthologues:

Amyloid P Component, Serum

Ensembl ID : ENSJJAG00000013862
Gene Symbol: APCS
3 Cross references
440 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSJJAG00000018436
Gene Symbol: APP
3 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSJJAG00000017196
Gene Symbol: AR
2 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).